Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

Psilocybin therapy significantly decreased moderate to severe symptoms of depression in clinicians after frontline work ...

Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Innovative research to assess the effectiveness of digital and talking therapies for anxiety and depression has been given a ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

Depression speeds up physical illness. A study shows adults with depression develop conditions 30% faster. Read more.

Supernus Pharmaceuticals (NASDAQ:SUPN) lost ~20% in the premarket on Wednesday after the neuro-focused biopharma said its ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...